We don’t fill tissue.
We rebuild it.
AxCell Labs is developing regenerative soft tissue implants that restore volume and guide the formation of living, vascularized tissue — starting with a new generation of regenerative dermal injectables.
Powered by a novel implantable biomaterial derived from
bacterial cellulose.
Products
Regenerative Dermal Injectable
- Restores volume
- Supports tissue regeneration
- Designed for soft tissue reconstruction
ENT Soft Tissue Implant (in dev.)
- For structural soft tissue repair
- Designed as biosynthetic cartilage for ENT reconstruction
Current solutions
fall short
- Temporary fillers require repeated treatments
- Particulate injectables do not integrate with tissue
- Synthetic implants can trigger inflammation and fibrosis
We take a regenerative approach — rebuilding tissue rather than simply filling or stimulating it.
Partners
Working with clinicians, researchers, and industry leaders to bring regenerative implants to the clinic.
About us
AxCell Labs is a Canadian medical device company developing a new class of regenerative soft tissue implants designed to enable true tissue reconstruction.
Founded in 2021, the company has developed a proprietary purification process enabling the safe use of this biomaterial in implantable applications. AxCell has completed preclinical biocompatibility studies, filed a PCT patent, and raised $1.4M in pre-seed funding.
The company is currently advancing its lead product — a regenerative dermal injectable — toward regulatory preclinical studies, with the goal of initiating first-in-human trials.